Persistent SARS-CoV-2 Alpha Variant Infection in Immunosuppressed Patient, France, February 2022.
Alpha variant
COVID-19
France
SARS
SARS-CoV-2
coronavirus
coronavirus disease
mutations
respiratory infections
severe acute respiratory syndrome coronavirus 2
viruses
zoonoses
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
pubmed:
7
5
2022
medline:
22
6
2022
entrez:
6
5
2022
Statut:
ppublish
Résumé
We describe persistent circulation of SARS-CoV-2 Alpha variant in an immunosuppressed patient in France during February 2022. The virus had a new pattern of mutation accumulation. The ongoing circulation of previous variants of concern could lead to reemergence of variants with the potential to propagate future waves of infection.
Identifiants
pubmed: 35514025
doi: 10.3201/eid2807.220467
pmc: PMC9239896
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1512-1515Références
Cell Host Microbe. 2022 Feb 9;30(2):154-162.e5
pubmed: 35120605
Emerg Infect Dis. 2021 Oct;27(10):2725-2728
pubmed: 34352197
Nat Commun. 2021 Nov 4;12(1):6405
pubmed: 34737266
Cell. 2020 Dec 23;183(7):1901-1912.e9
pubmed: 33248470
Genome Med. 2021 Feb 22;13(1):30
pubmed: 33618765
PLoS Pathog. 2022 Jan 12;18(1):e1010242
pubmed: 35020754
N Engl J Med. 2020 Dec 3;383(23):2291-2293
pubmed: 33176080
Biomedicines. 2021 Jul 13;9(7):
pubmed: 34356872
N Engl J Med. 2021 Aug 5;385(6):562-566
pubmed: 34347959